The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...

Karmanos 1st debut novel gene therapy offers a one-time treatment for adult hemophilia B, reducing the need for routine factor IX infusions.

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...

Global stockout halts access to Hemgenix gene therapy, delaying treatment for adults with hemophilia B amid manufacturing challenges.

The discounted drugs from German manufacturer Boehringer Ingelheim are Jentadueto and Jentadueto XR, for Type 2 diabetes, as well as the COPD drug Striverdi Respimat, NBC News reported. Plus, the ...

The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide a new hemophilia treatment. Etranacogene dezaparvovec-drlb, also known by its ...

In an open letter to the Hemophilia B Community, CSL Limited vice president medical affairs, Dr Deborah Long shared an important update on the availability of Hemgenix (etranacogene dezaparvovec-drlb) ...

A new study could explain why some mothers can still pass Group B Streptococcus, or GBS, to their babies after childbirth ...

Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily ...

Macau Drug Administration approves Belief Pharmaceuticals’ haemophilia B gene therapy drug, Popidacoji injection: Shanghai, China Saturday, March 21, 2026, 17:00 Hrs [IST] Belie ...

A small survey in Germany found many men with severe hemophilia are not interested in gene therapy, which may suggest gaps in patient info.

The Chinese biotech company received regulatory clearance for its BBM-H901 treatment, marking the country's inaugural gene therapy for the bleeding disorder.